Elsevier

Brain Research

Volume 288, Issues 1–2, 12 December 1983, Pages 213-218
Brain Research

A subcortico-cortical cholinergic system is affected in Parkinson's disease

https://doi.org/10.1016/0006-8993(83)90096-3Get rights and content

CAT activity was decreased in the frontal cortex and the substantia innominata of parkinsonians subjects, post-mortem. The decrease was greater in the frontal cortex of parkinsonians with dimentia. The density of muscarinic cholinergic receptors increased in the cortex. This increase was inversely correlated with tremor. The effectsof these parameters of both neuronal degeneration and anticholinergic therapy are discussed.

References (22)

  • HakimA.M. et al.

    Dementia in Parkinson disease: a neuropathologic study

    Neurology

    (1979)
  • Cited by (151)

    • Compensatory dopaminergic-cholinergic interactions in conflict processing: Evidence from patients with Parkinson's disease

      2019, NeuroImage
      Citation Excerpt :

      The heterogeneity of neuromodulator system decline in Parkinson's disease (PD) may make it particularly instructive. In addition to the dopaminergic declines that define the disorder, Parkinson's patients often have degeneration along other neural pathways (cholinergic, noradrenergic, serotonergic, etc.; Dunois et al., 1983; Gaspar et al., 1991; Halliday et al., 1990; Kuhls et al., 1996; Rommelfanger and Weinshenker, 2007; Scatton et al., 1983; Stern et al., 1984). There are large individual differences in the degree of degeneration in these other pathways, and those differences can be relatively independent of each other and of the degree of dopaminergic decline (e.g., Bohnen and Albin, 2011; Dunois et al., 1983; Hall et al., 2014; Monchi et al., 2016; Müller and Bohnen, 2013; Perry et al., 1985; Pillon et al., 1989).

    • G protein-coupled receptors in neurodegenerative diseases

      2019, GPCRs: Structure, Function, and Drug Discovery
    • Imaging the Nonmotor Symptoms in Parkinson's Disease

      2017, International Review of Neurobiology
      Citation Excerpt :

      Although the authors did not use a uniform cognitive assessment, a correlation between striatal dopaminergic deficits and cognitive impairment was a common finding (Duchesne et al., 2002; Muller et al., 2000; Pellecchia et al., 2015). The pathophysiology of cognitive impairment may also encompass cholinergic dysfunction within the brainstem and corticostriatal pathway, as initially demonstrated by postmortem studies which reported a profound reduction of cytosolic enzyme choline acetyltransferase (ChAT) in the substantia nigra pars compacta, hippocampus, and especially in the neocortex of PD patients with and without dementia (Dubois, Ruberg, Javoy-Agid, Ploska, & Agid, 1983; Lange, Wells, Jenner, & Marsden, 1993; Ruberg, Ploska, Javoy-Agid, & Agid, 1982). Molecular imaging techniques including PET and SPECT employing radioligands selectively targeting the cholinergic system have led to significant strides in our knowledge of the pathophysiology of cognitive impairment and dementia (Roy et al., 2016).

    View all citing articles on Scopus
    View full text